FGFR2 (K526E)

FGFR2 · Variant type: point · HGVS: p.K526E

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Pemigatinib	100.0%	0.0%	98.23
2	Futibatinib	100.0%	0.0%	98.48
3	Alpelisib	100.0%	0.0%	97.22
4	Ponatinib	99.4%	0.6%	78.23
5	Nintedanib	99.0%	1.0%	90.23
6	Tenalisib	98.9%	1.1%	97.98
7	Regorafenib	98.7%	1.3%	95.99
8	Pralsetinib	98.7%	1.3%	93.43
9	Axitinib	98.7%	1.3%	93.23
10	Erdafitinib	98.7%	1.4%	95.71
11	Vandetanib	98.3%	1.7%	95.74
12	Selpercatinib	98.3%	1.8%	96.72
13	Infigratinib	98.2%	1.8%	98.24
14	Deucravacitinib	97.6%	2.4%	98.99
15	Lenvatinib	97.1%	2.9%	97.74
16	Ripretinib	96.9%	3.1%	92.95
17	Brigatinib	96.6%	3.4%	82.96
18	Tivozanib	96.2%	3.8%	92.42
19	Pazopanib	95.1%	4.9%	97.49
20	Repotrectinib	94.1%	5.9%	84.21
21	Sunitinib	91.7%	8.3%	91.73
22	Canertinib	90.2%	9.8%	96.49
23	Fedratinib	88.1%	11.9%	96.21
24	Entrectinib	87.9%	12.1%	93.69
25	Sorafenib	87.4%	12.6%	96.72

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Pemigatinib	100.0%	98.7%	+1.3%
Futibatinib	100.0%	99.3%	+0.7%
Alpelisib	100.0%	98.9%	+1.1%
Ponatinib	99.4%	99.4%	+0.0%
Nintedanib	99.0%	97.0%	+2.0%
Tenalisib	98.9%	96.0%	+2.9%
Regorafenib	98.7%	—	—
Pralsetinib	98.7%	93.2%	+5.5%
Axitinib	98.7%	96.1%	+2.5%
Erdafitinib	98.7%	99.0%	-0.3%
Vandetanib	98.3%	90.8%	+7.5%
Selpercatinib	98.3%	95.0%	+3.2%
Infigratinib	98.2%	98.8%	-0.6%
Deucravacitinib	97.6%	92.5%	+5.1%
Lenvatinib	97.1%	85.4%	+11.8%
Ripretinib	96.9%	85.4%	+11.6%
Brigatinib	96.6%	96.1%	+0.5%
Tivozanib	96.2%	—	—
Pazopanib	95.1%	88.9%	+6.2%
Repotrectinib	94.1%	79.8%	+14.3%
Sunitinib	91.7%	—	—
Canertinib	90.2%	—	—
Fedratinib	88.1%	—	—
Entrectinib	87.9%	81.5%	+6.3%
Sorafenib	87.4%	—	—

Cancer	Organ	Source
endometrial_carcinoma	Uterus	ref
carcinoma_liver	Liver	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 14.3ms